奥妥珠单抗暴露不影响已接种疫苗的新诊断晚期滤泡性淋巴瘤患者SARS-CoV-2感染的结局
URBAN研究是一项多中心、双向性研究,评估奥妥珠单抗为基础免疫化疗及维持治疗在初治晚期滤泡性淋巴瘤(FL)中的有效性与安全性。结果显示疫苗接种前后COVID-19相关死亡率大幅下降,且随变异株从alpha/delta转为omicron优势,COVID-19相关结局减少;接受与未接受维持治疗的患者间无差异,尽管65%病例维持方案有所调整。
要点
- 疫苗接种前后COVID-19相关死亡率大幅下降,alpha/delta向omicron转变后COVID-19相关结局减少。
- 接受与未接受维持治疗的患者间COVID-19相关结局无差异,尽管65%病例维持方案有调整。
核心结论
- 奥妥珠单抗暴露不影响已接种疫苗的新诊断晚期滤泡性淋巴瘤患者SARS-CoV-2感染的结局。
研究设计与样本
- URBAN为多中心、双向性研究,评估奥妥珠单抗为基础免疫化疗及维持治疗在初治晚期滤泡性淋巴瘤患者中的有效性与安全性。
- 研究始于意大利COVID-19紧急状态声明之前,目前仍在随访中,入组时间涵盖疫情不同阶段、疫苗接种推广各阶段及SARS-CoV-2变异株流行期。
主要发现
- 294例(98.3%)完成诱导治疗,31例(10.4%)完成维持治疗,170例(56.9%)仍在维持治疗中。
- 245例(81.9%)至少接种一剂SARS-CoV-2疫苗:分别有13.5%、31.4%和55.1%接种一剂、两剂和三剂。
- 疫苗接种前后COVID-19相关死亡率大幅下降,且随alpha/delta向omicron变异株优势转变,COVID-19相关结局减少。
- 接受与未接受维持治疗的患者间无差异,尽管65%病例维持方案有所调整。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
URBAN is a multicentric, ambispective study evaluating the effectiveness and safety of obinutuzumab-based immuno-chemotherapy and maintenance in patients with untreated advanced follicular lymphoma (FL). The study began before the COVID-19 emergency declaration in Italy. It is currently ongoing for follow-up, and the enrolment timeline encompassed different stages of the pandemic, various vaccination roll-out phases and prevalence of SARS-CoV-2 variants. Outcomes of interest of the present sub-analysis included SARS-CoV-2 infection rates and COVID-19-related hospitalizations/deaths. At data cut-off, 86 (28.8%) and 213 patients (71.2%) were treated before and during/after the COVID-19 outbreak respectively; 294 (98.3%) completed the induction, 31 (10.4%) completed maintenance and 170 (56.9%) were still on maintenance. Overall, 245 patients (81.9%) received at least one SARS-CoV-2 vaccine dose: 13.5%, 31.4% and 55.1% received one, two and three doses respectively. We observed a substantial decrease in COVID-19-related mortality rates in pre- versus post-vaccination phases, along with a reduction in COVID-19-related outcomes due to the shift from alpha/delta to omicron variant predominance. No differences emerged between patients given maintenance or not, although the schedule was modified in 65% of cases. To our knowledge, URBAN represents the largest dataset of COVID-19-related outcomes in FL patients extensively exposed to obinutuzumab. ClinicalTrials.gov identifier: NCT04034056.
引用
- Pinto A, Caltagirone M, Battista M, et al. Exposure to obinutuzumab does not affect outcomes of SARS-CoV-2 infection in vaccinated patients with newly diagnosed advanced-stage follicular lymphoma. Br J Haematol. 2024. PMID: 39039666. doi:10.1111/bjh.19661
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。